Bonk (SHOT) investor relations material

Executive summary

• Revenue for Q1 2026 was $4.34 million, a significant increase from $42,101 in Q1 2025, driven by the addition of Yerbaé Brands and a revenue share agreement with LetsBonk.fun.

• Net loss for Q1 2026 was $1.83 million, a substantial improvement from a net loss of $5.33 million in Q1 2025.

• The company completed a clinical trial for its Sure Shot Dietary Supplement, showing statistically significant reductions in blood alcohol content and improvements in cognitive function.

• Strategic repositioning included a name change to Bonk, Inc. and a focus on digital assets and decentralized finance initiatives.

Financial highlights

• Gross profit for Q1 2026 was $3.59 million, compared to $20,989 in Q1 2025.

• Operating expenses decreased to $2.22 million in Q1 2026 from $5.41 million in Q1 2025.

• Other income included a $796,404 gain on sale of marketable securities and an unrealized loss of $3.83 million on digital assets.

• Cash at March 31, 2026 was $728,907, down from $2.28 million at year-end 2025.

• Accumulated deficit stood at $185.3 million as of March 31, 2026.

Outlook and guidance

• Management continues to focus on expanding the Sure Shot product line and digital asset initiatives.

• The company acknowledges substantial doubt about its ability to continue as a going concern due to ongoing losses and limited cash resources.